Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 4Endocrine 3NET 2Gastrointestinal 2

Conditions

Neuroendocrine Tumors 35Carcinoid Tumor 8Adenoma, Islet Cell 6Neoplasms 5Neoplasm Metastasis 3Carcinoma, Neuroendocrine 3Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Tuberous Sclerosis 1Thymus Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Metatropic dwarfism 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Glioblastoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1

Interventions

Sunitinib 2Everolimus 2repotrectinib 1pralsetinib 1pasireotide 1lutetium Lu 177 dotatate 1epothilone B 1cixutumumab 1avelumab 1Radiotherapy 1Octreotide 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Everolimus × NET × Clear all
NCT00688623 2019-01-25

RAMSETE/CDE16

Novartis

Phase 2 Completed
73 enrolled 13 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT00363051 2013-05-10

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Novartis

Phase 2 Completed
160 enrolled 17 charts
EndocrineGastrointestinalNET

Carcinoma, Neoplasms, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡